WuXi XDC
Manufacturing · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
No.4 Building No. 800 Qifan Rd, Shanghai...Website
www.wuxixdc.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About WuXi XDC
WuXi XDC is a leading Contract Research, Development and Manufacturing Organization (CRDMO) that specializes in providing end-to-end solutions for antibody drug conjugates (ADCs) and other bioconjugates. Their comprehensive services include bioconjugation discovery, process development, analytical development, and GMP manufacturing, all designed to streamline the drug development process. With a focus on innovation and efficiency, WuXi XDC aims to help global clients bring high-quality biotherapeutics to market quickly. The company serves a diverse range of clients in the biopharmaceutical industry, leveraging its extensive expertise and integrated capabilities.Explore more
WuXi XDC Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is WuXi XDC your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once WuXi XDC has new funding data
WuXi XDC, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if WuXi XDC had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at WuXi XDC
Check out if WuXi XDC is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on WuXi XDC recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if WuXi XDC has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when WuXi XDC launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
WuXi XDC is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
WuXi XDC is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about WuXi XDC.
WuXi XDC Tech Stack
A closer look at the technologies used by WuXi XDC
Most Recent Scoops
Earnings
WuXi XDC has reported an adjusted net profit exceeding RMB 1 billion for H1 2026, marking the first time this threshold has been reached in a six-month period, with an adjusted net profit margin of approximately 27.8%.
Earnings, Finance
Project
WuXi XDC has reported that approximately three-quarters of the 51 integrated CMC (ICMC) contracts signed in H1 2026 represent newer modality types, including novel targets, novel payloads, bispecific ADCs, dual payload ADCs, antibody-drug conjugates, antibody-peptide conjugates, and other novel conjugate formats.
Pharmaceuticals, Contracts
Earnings
WuXi XDC has provided a long-term financial and pipeline outlook, anticipating 4 to 6 BLA submissions in 2026, over 60 PPQ component executions and 12 to 15 BLA submissions by 2028, and a target of 20% of revenue each from newer XDC modalities and commercial manufacturing by 2030.
Financial Planning, Forecasting, Finance, Financial Strategy
Hiring Plans
WuXi XDC has more open roles in Engineering & Technical than it has had at any time in the past 12 months.
Hiring Plans
Event
Product Marketing, Events, Engineering, Research & Development, Contingent Workforce, Sales, Business Development, Outsourcing, Search, Bioengineering, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, HR Operations, Manufacturing Operations, Operations, Organizational Development
WuXi XDC News & Media
WuXi XDC Cayman Inc (STU:L74) (H1 2026) Earnings Call Highlights: Record Backlog and First $1B ...
WuXi XDC Cayman Inc (STU:L74) reports 37% revenue growth and a record service backlog of nearly $2 billion, while navigating margin pressures from new investments.WuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO Leadership
Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER[1] basis (41.5% growth on a CER[2] basis) Gross profit grew by 40.6% period-over-period, reaching RMB 1,371.3 million. Gross profit margin was 37.0%, a 0.9 percentage points...WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence
SINGAPORE, Aug. 18, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that its BCM3 dual-function production line for...WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence
SINGAPORE, Aug. 18, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that its BCM3 dual-function production line for antibody intermediates and drug substances of bioconjugates at Singapore site has successfully achieved GMP release. This milestone marks a new phase in the company's global capacity expansion, empowering clients w
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding WuXi XDC
Sign Up For FreeTo access detailed company insights
WuXi XDC is a leading Contract Research, Development and Manufacturing Organization (CRDMO) that specializes in providing end-to-end solutions for antibody drug conjugates (ADCs) and other bioconjugates. Their comprehensive services include bioconjugation discovery, process development, analytical development, and GMP manufacturing, all designed to... Read More
